EDP-M (etoposide + doxorubicin + cisplatin + mitotane) — FIRM-ACT regimen
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Composantes | DRUG-ETOPOSIDE DRUG-DOXORUBICIN DRUG-CISPLATIN DRUG-MITOTANE |
|---|
| ID | REG-EDP-M-ACC |
|---|---|
| Type | Protocole thérapeutique |
| État | reviewed 2026-07-11 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-ENSAT-ACC-2018 SRC-ESMO-ACC-2020 SRC-FIRM-ACT-FASSNACHT-2012 |
Notes
STUB pending clinical co-lead sign-off (CHARTER §6.1). Regimen doses and schedule (etoposide 100 mg/m² days 2-4, doxorubicin 40 mg/m² day 1, cisplatin 40 mg/m²/day days 3-4, every 28 days, plus continuous mitotane targeting 14-20 mg/L) reproduced from the FIRM-ACT trial (Fassnacht 2012 NEJM) as corroborated by secondary search sources this session; verify against the primary NEJM publication before clinical use. FIRM-ACT results: response rate 23.2% (EDP-M) vs 9.2% (streptozocin+mitotane), p<0.001; median PFS 5.0 vs 2.1 months; median OS 14.8 vs 12.0 months (p=0.07, not significant — confounded by permitted crossover at progression). EDP-M is the preferred 1L combination based on the response/PFS advantage. Per the disease-level "mitotane +/- EDP" narrative, mitotane monotherapy alone (without full EDP) remains a reasonable alternative for patients unfit for combination cytotoxic chemotherapy or with more indolent/lower-burden disease — not separately authored as a distinct Regimen/Indication in this KB pass (see ALGO-ACC-1L step 3 null-branch notes).
Utilisé par
Indication
IND-ACC-1L-MITOTANE-EDP- IND-ACC-1L-MITOTANE-EDP